Intensive intravenous chelation therapy in thalassemic patients with iron overload;Chelazione intensiva per via venosa in pazienti talassemici ipersiderotici

Minerva Pediatrica

Volumn 50, Issue 3, 1998, Pages 81-85

  Di Gregorio, F ^a,b   Leonardi, C ^a   Sciuto, C ^a   Cannella, A ^a   Pizzarelli, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Centro di Microcitemia   (Italy)

Author keywords

Beta thalassemia; Chelation therapy; Deferoxamine therapeutic use

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATE;

ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; FERRITIN BLOOD LEVEL; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; CHELATION THERAPY; DEFEROXAMINE; ECHOCARDIOGRAPHY; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; THALASSEMIA; TIME FACTORS;

EID: 0031873533     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cohen A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987;1:521-3.
2. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Di Gregorio F et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-9.
3. Modell B, Beck J. Long term desferrioxamine therapy in thalassaemia. Ann NY Acad Sci 1974;232:201.
4. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassaemia major. N Engl J Med 1985,312:1600-3.
5. Di Gregorio F, Romeo MA, Tasca R, Passanisi G. Compliance alla terapia ferrochelante di pazienti affetti da beta talassemia major. Minerva Pediatr 1983;35:489-93.
6. Cohen A, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatric 1989;115:151-5.
7. Bachelot C, Plantaz D. Administration intraveineuse de deferoxamine en hospitalisation de nuit: efficacité et bonne tolérance psychologique pour les enfants thalassemiques. Pédiatrie 1990;45.619-23.
8. Davies SC, Hungerford JL, Arden GB, Marcus RE, Miller MH, Huchns ER Ocular tossicity of high intravenous deferoxamine. Lancet 1983;23:181-4.
9. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;34:869-73.
10. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR. Growth and development in thalassemia major patients with severe bone lesions due to deferoxamine. Eur J Pediatr 1996;155:368-72.
11. Dudley RF. Chemiluminiscence. Immunoassay Lab Med 1990,21:216.
12. Propper RD, Shurin SB, Nathan DG. Reassessment of use of deferoxamine in iron overload N Engl J Med 1976,294:1421-3.
13. Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine Am J Hematol 1992;41:61-3
14. Lombarde T, Ferro G, Frontini V, Percolla S Highdose intravenous deferoxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Am J Hematol 1996;51:90-2.
15. Spinto P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echo-cardiography in patients with thalassaemia major. Circulation 1990,82.88-94.
16. Brittenham G, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE et al Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major N Engl J Med 1994;331:567-73.
17. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE et al. High incidence of cardiomyopathy in beta thalassaemia patients receiving regular transfusion and iron chelation. reversal by intensified chelation. Acta Haematol 1990,84:113-7.
18. Olivieri N, Nathan G, Mac Millan JH, Wayne AS, Liu P, McGee A et al. Survival in medically treated patients with homozygous β thalassaemia. N Engl J Med 1994;331:574-8.
19. Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R et al. Acute changes in renal function associated with deferoxamine therapy. AJDC 1989;143 1077-80.
20. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS Pulmonary syndrome in patients with thalassaemia major receiving intravenous deferoxamine infusions. AJDC 1990;144:565-9.
21. Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M et al. Toxic effects of high dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica 1991;76:131-4.